Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism

Rheumatology (Oxford). 2007 Jun;46(6):1034-5. doi: 10.1093/rheumatology/kem041. Epub 2007 Apr 4.

Authors

A Chatzikyriakidou, I Georgiou, P V Voulgari, A I Venetsanopoulou, A A Drosos

PMID: 17409133
DOI: 10.1093/rheumatology/kem041

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Female
Genotype
Humans
Infliximab
Male
Middle Aged
Prognosis
Receptors, Tumor Necrosis Factor / genetics*
Treatment Outcome
Tumor Necrosis Factor-alpha / genetics*

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Infliximab